Literature DB >> 3937430

Long-term results of GnRH analogue (Buserelin) treatment in girls with central precocious puberty.

R Brauner, E Thibaud, P Bischof, P C Sizonenko, R Rappaport.   

Abstract

The GnRH analogue Buserelin was given for one year to six girls with central precocious puberty in a daily subcutaneous dose of 20 micrograms/kg/day. A decrease of plasma estradiol and vaginal maturation index to prepubertal values was obtained in 5 out of 6 cases. Bone maturation decreased and final predicted adult height improved significantly. This analogue of GnRH appears to be an effective medication for gonadotropin dependent precocious puberty in girls.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3937430     DOI： 10.1111/j.1651-2227.1985.tb10062.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN： 0001-656X


  5 in total

1.  Precocious puberty in girls: early diagnosis of a slowly progressing variant.

Authors:  M Fontoura; R Brauner; C Prevot; R Rappaport
Journal:  Arch Dis Child       Date:  1989-08       Impact factor: 3.791

2.  The effect of cyproterone acetate on the growth of children with central precocious puberty.

Authors:  R Stanhope; K F Huen; F Buzi; M A Preece; D B Grant
Journal:  Eur J Pediatr       Date:  1987-09       Impact factor: 3.183

3.  Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins.

Authors:  J L Rime; U Zumsteg; A Blumberg; F Hadziselimovic; J Girard; R P Zurbrügg
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

Review 4.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

5.  Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin).

Authors:  J P Bourguignon; G Van Vliet; M Vandeweghe; P Malvaux; M Vanderschueren-Lodeweyckx; M Craen; M V Du Caju; C Ernould
Journal:  Eur J Pediatr       Date:  1987-11       Impact factor: 3.183
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.